Twist Bioscience (NASDAQ:TWST) Price Target Raised to $55.00

Twist Bioscience (NASDAQ:TWST) had its price objective upped by equities researchers at Guggenheim from $50.00 to $55.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price target would indicate a potential upside of 23.13% from the stock’s previous close.

Several other equities research analysts have also commented on TWST. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday. Barclays upped their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, February 3rd. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, February 3rd. Finally, Evercore lifted their price objective on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $46.50.

Twist Bioscience Price Performance

Shares of TWST traded up $0.14 on Monday, reaching $44.67. The stock had a trading volume of 148,096 shares, compared to its average volume of 1,307,907. Twist Bioscience has a twelve month low of $23.30 and a twelve month high of $57.88. The firm has a market capitalization of $2.74 billion, a PE ratio of -34.90 and a beta of 2.23. The firm has a 50-day moving average of $46.47 and a 200 day moving average of $36.66. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The firm had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The firm’s revenue was up 16.9% compared to the same quarter last year. Sell-side analysts expect that Twist Bioscience will post -2.12 EPS for the current year.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 5,001 shares of Twist Bioscience stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total transaction of $232,946.58. Following the completion of the sale, the chief executive officer directly owned 869,312 shares in the company, valued at $40,492,552.96. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Adam Laponis sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $50.00, for a total transaction of $350,000.00. Following the completion of the transaction, the chief financial officer directly owned 130,031 shares of the company’s stock, valued at approximately $6,501,550. This represents a 5.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 48,190 shares of company stock worth $2,234,695 in the last 90 days. 3.08% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Campbell & CO Investment Adviser LLC increased its stake in Twist Bioscience by 227.6% in the third quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company’s stock valued at $1,328,000 after purchasing an additional 32,792 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Twist Bioscience by 14.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company’s stock worth $41,171,000 after buying an additional 184,726 shares during the last quarter. Baillie Gifford & Co. boosted its stake in Twist Bioscience by 62.8% in the 3rd quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company’s stock worth $35,533,000 after buying an additional 487,052 shares during the last quarter. William Blair Investment Management LLC grew its holdings in Twist Bioscience by 6.0% in the 3rd quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company’s stock valued at $116,564,000 after buying an additional 235,679 shares during the period. Finally, First Light Asset Management LLC increased its stake in shares of Twist Bioscience by 26.4% during the 3rd quarter. First Light Asset Management LLC now owns 1,194,883 shares of the company’s stock valued at $33,624,000 after acquiring an additional 249,850 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.